CERT Certara

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.

Investors interested in listening to the conference call are required to It is recommended to register at least one day in advance.

Certara also announced that Company management will participate at the upcoming BofA Securities Healthcare Conference.

Company management will present at 3:40PM PT on Tuesday, May 14th.

Live and archived webcasts of both the financial results conference call and the BofA presentation will be available on the “Investors” section of the Certara website at .

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries. Visit us at .

Investor Relations Contact:

David Deuchler

Gilmartin Group

Media Contact:

Pan Communications

 

 



EN
09/04/2024

Underlying

CERTCertara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE
Free
CERT CERTARA

Certara Reports Second Quarter 2025 Financial Results 

Certara Reports Second Quarter 2025 Financial Results  Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million, compared to $38.2 million in the second quarter of 2024, representing growth of 22%.Service revenue ...

August 6, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Simcyp® Simulator Becomes First and Only Software Platform to ...

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. Certara is the first company to receive EMA qualification for a PBPK modeling platform, and Simcyp is the only software to hold this designation. The recognition follows a rigorous multi-year, collaborative engagement between ...

August 4, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advan...

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-gene...

July 31, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara to Report Second Quarter 2025 Financial Results on August 6th,...

Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025 RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to It is recommended to register at least one day in advance. A live and archived webc...

July 9, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Announces Expansion of Clinical Technology Collaboration with ...

Certara Announces Expansion of Clinical Technology Collaboration with Merck Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This agreement...

July 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch